Gemcitabine plus Capecitabine Combination in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines and Taxanes
Authors:
- Mustafa BenekliMBMustafa Benekli
- Ramazan YildizRYRamazan Yildiz
- Aytug UnerAUAytug Uner
- Ozlem ErOEOzlem Er
- Deniz YamacDYDeniz Yamac
- Necati AlkisNANecati Alkis
- Ugur CoskunUCUgur Coskun
- Celalettin CamciCCCelalettin Camci
- Suleyman BuyukberberSBSuleyman Buyukberber
- 1 January 2007
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 72 (5-6) , 308-313
Abstract
Background: Treatment of patients with metastatic breast cancer (MBC) exposed to anthracyclines and taxanes is challenging. Effective and well-tolerated regimens are required. Gemcitabine plus capecitabine combination was assessed in MBC patients pretreated with anthracyclines and taxanes. Patients and Methods: A total of 31 patients treated between November 2004 and September 2005 were retrospectively evaluated in 4 institutions. The median age was 48 years (range 29–77). The patients were given gemcitabine 1,000 mg/m2 on days 1 and 8, and capecitabine 1,500 mg/m2 twice daily on days 1–14 every 3 weeks. Results: A total of 160 cycles of chemotherapy were administered with a median of 5 cycles per patient (range 2–12). Three patients achieved a partial response (10%) and 8 patients (26%) stable disease. The median time to disease progression was 6 months (95% CI 5–7), with a median survival of 18 months (95% CI 15–21) at a median follow-up of 16 months (range 2–28). One-year and 2-year survival rates were 67 and 28%, respectively. Grade 3–4 toxicities were as follows: neutropenia (n = 11, 35%), nausea and vomiting (n = 4, 13%), hand-foot syndrome (n = 2, 6%), anemia (n = 2, 6%), thrombocytopenia (n = 2, 6%) and asthenia (n = 1, 3%). Conclusion: The combination of gemcitabine plus capecitabine was a tolerable regimen with a mild but comparable survival efficacy to similar regimens in patients with MBC after anthracyclines and taxanes.Keywords
This publication has 24 references indexed in Scilit:
- A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancerAnti-Cancer Drugs, 2006
- Goals of Treatment for Patients With Metastatic Breast CancerSeminars in Oncology, 2006
- Extending Survival with Chemotherapy in Metastatic Breast CancerThe Oncologist, 2005
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerEuropean Journal of Cancer, 2004
- Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and TaxaneJournal of Korean Medical Science, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancerAnti-Cancer Drugs, 1999
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958